SCHEMBL18249555

SCHEMBL18249555

NCCOc1cc(N)c2ncccc2c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 3/20 0.44
HSP90AB1 P08238 3/20 0.44
KDM4E B2RXH2 7/20 0.43
MAPT P10636 4/20 0.43
TAAR1 Q96RJ0 1/20 0.42
LMNA P02545 4/20 0.41
CYP1A2 P05177 3/20 0.41
CYP3A4 P08684 2/20 0.41
CYP2D6 P10635 2/20 0.41
CYP2C19 P33261 2/20 0.41
CASP1 P29466 2/20 0.41
ABCB11 O95342 1/20 0.41
ESR1 P03372 1/20 0.41
PGR P06401 1/20 0.41
ADRB2 P07550 1/20 0.41
CHRM2 P08172 1/20 0.41
ADRB1 P08588 1/20 0.41
HTR1A P08908 1/20 0.41
ADRA2A P08913 1/20 0.41
ADORA3 P0DMS8 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18249539 0.89 KDM4E (0.42) HSP90AA1HSP90AB1KDM4EMAPTLMNA
SCHEMBL2473645 0.85 KDM4E (0.45) HSP90AA1HSP90AB1KDM4EMAPTLMNA
SCHEMBL8439027 0.83 SLC40A1 (0.52) HSP90AA1HSP90AB1KDM4EMAPTLMNA
SCHEMBL18249542 0.82 CHRNB2 (0.49) HSP90AA1HSP90AB1KDM4EMAPTLMNA
SCHEMBL5330815 0.79 CYP3A4 (0.55) KDM4EMAPTCYP3A4MAOAMAOB
SCHEMBL454942 0.79 CYP1A2 (0.55) HSP90AA1HSP90AB1KDM4EMAPTLMNA
Bromide SCHEMBL1143538 0.78 CYP1A2 (0.53) HSP90AA1HSP90AB1KDM4EMAPTLMNA
SCHEMBL18249540 0.77 HSP90AA1 (0.57) HSP90AA1HSP90AB1KDM4EMAPTLMNA
SCHEMBL18249533 0.76 NPC1 (0.49) KDM4ECYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL18249536 0.76 SLC6A2 (0.43) CYP1A2CYP2D6CYP2C19ADORA3SLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10457662-B2 Substituted amides for treating and preventing cancer THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2019-10-29 US disclosed
US-20180282296-A1 COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING CANCER THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM 2018-10-04 US disclosed
WO-2016187544-A1 COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING CANCER THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2016-11-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180282296-A1 COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING CANCER NNT, NQO1, NAMPT HSP90AA1 2976/4885HSP90AB1 2595/4885KDM4E 2863/4885
US-10457662-B2 Substituted amides for treating and preventing cancer NQO1, NNT, SIRT1 HSP90AA1 2070/4885HSP90AB1 1900/4885KDM4E 1342/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.